Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

Paz-Ares, L; Champiat, S; Lai, WV; Izumi, H; Govindan, R; Boyer, M; Hummel, HD; Borghaei, H; Johnson, ML; Steeghs, N; Blackhall, F; Dowlati, A; Reguart, N; Yoshida, T; He, K; Gadgeel, SM; Felip, E; Zhang, YR; Pati, A; Minocha, M; Mukherjee, S; Goldrick, A; Nagorsen, D; Sadraei, NH; Owonikoko, TK

Paz-Ares, L (通讯作者)，Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain.

JOURNAL OF CLINICAL ONCOLOGY, 2023; 41 (16): 2893

Abstract

PURPOSE Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments. Delta-like ligand 3 (DLL3) is aberrantly expressed in most ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索